Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Michelson

Showing results (21-30 of 89) with videos related to

Pageof 9
Sort By:
Pediatrics|July 5, 2005
Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorderThomas J Spencer, Jeffrey H Newcorn, Christopher J Kratochvil, et al.
Behavioral and Brain Functions : BBF|October 6, 2005
Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysisStephen V Faraone, Joseph Biederman, Thomas Spencer, et al.
Sleep Medicine|May 21, 2016
Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 dataEllen Snyder, Junshui Ma, Vladimir Svetnik, et al.
Pediatrics|November 15, 2006
Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorderJeffrey H Newcorn, David Michelson, Christopher J Kratochvil, et al.
Journal of Attention Disorders|July 13, 2005
Training raters to assess adult ADHD: reliability of ratingsLenard A Adler, Thomas Spencer, Stephen V Faraone, et al.
The Journal of Clinical Psychiatry|April 21, 2004
Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetineMelissa J Joliat, Mark E Schmidt, Maurizio Fava, et al.
Schizophrenia Research|March 26, 2013
Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophreniaMichael F Egan, Xin Zhao, Regina Gottwald, et al.
Sleep Medicine|December 8, 2018
Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 dataW Joseph Herring, Kathryn M Connor, Ellen Snyder, et al.
Cephalalgia : an International Journal of Headache|August 10, 2014
Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxisAlmira Chabi, Ying Zhang, Saheeda Jackson, et al.
The Journal of Clinical Psychiatry|May 3, 2006
Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidityThomas J Spencer, Stephen V Faraone, David Michelson, et al.
Pageof 9

Showing results (21-30 of 89) with videos related to

Sort By:
Pageof 9
Pediatrics|July 5, 2005
Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorderThomas J Spencer, Jeffrey H Newcorn, Christopher J Kratochvil, et al.
Behavioral and Brain Functions : BBF|October 6, 2005
Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysisStephen V Faraone, Joseph Biederman, Thomas Spencer, et al.
Sleep Medicine|May 21, 2016
Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 dataEllen Snyder, Junshui Ma, Vladimir Svetnik, et al.
Pediatrics|November 15, 2006
Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorderJeffrey H Newcorn, David Michelson, Christopher J Kratochvil, et al.
Journal of Attention Disorders|July 13, 2005
Training raters to assess adult ADHD: reliability of ratingsLenard A Adler, Thomas Spencer, Stephen V Faraone, et al.
The Journal of Clinical Psychiatry|April 21, 2004
Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetineMelissa J Joliat, Mark E Schmidt, Maurizio Fava, et al.
Schizophrenia Research|March 26, 2013
Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophreniaMichael F Egan, Xin Zhao, Regina Gottwald, et al.
Sleep Medicine|December 8, 2018
Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 dataW Joseph Herring, Kathryn M Connor, Ellen Snyder, et al.
Cephalalgia : an International Journal of Headache|August 10, 2014
Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxisAlmira Chabi, Ying Zhang, Saheeda Jackson, et al.
The Journal of Clinical Psychiatry|May 3, 2006
Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidityThomas J Spencer, Stephen V Faraone, David Michelson, et al.
Pageof 9